Completed PHASE1 INTERVENTIONAL 1-arm NCT03177278

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

A Phase 1, Open-Label Study to Assess the Metabolism, Excretion, and Mass Balance of [14C]-Plazomicin Following a Single IV Infusion in Healthy Adult Male Subjects

Sponsor: Achaogen, Inc.

Conditions Healthy Volunteers

Interventions [14C]-plazomicin

Updated 6 times since 2017 Last updated: Jul 11, 2017 Started: Jun 16, 2017 Primary completion: Jul 10, 2017 Completion: Jul 10, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03177278, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Achaogen, Inc., it has been updated 6 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Jul 2017 — Aug 2017 [monthly]

Recruiting PHASE1

First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Achaogen, Inc.
Celerion

Data source: Achaogen, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States